- Home
- UEC vs VKTX Comparison
UEC vs VKTX Comparison
Compare UEC & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UEC
- VKTX
- Stock Information
- Founded
- UEC 2003
- VKTX 2012
- Country
- UEC United States
- VKTX United States
- Employees
- UEC N/A
- VKTX N/A
- Industry
- UEC Other Metals and Minerals
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- UEC Basic Materials
- VKTX Health Care
- Exchange
- UEC Nasdaq
- VKTX Nasdaq
- Market Cap
- UEC 3.9B
- VKTX 3.5B
- IPO Year
- UEC N/A
- VKTX 2015
- Fundamental
- Price
- UEC $10.52
- VKTX $26.00
- Analyst Decision
- UEC Strong Buy
- VKTX Strong Buy
- Analyst Count
- UEC 4
- VKTX 13
- Target Price
- UEC $10.75
- VKTX $86.92
- AVG Volume (30 Days)
- UEC 12.4M
- VKTX 9.0M
- Earning Date
- UEC 09-26-2025
- VKTX 07-23-2025
- Dividend Yield
- UEC N/A
- VKTX N/A
- EPS Growth
- UEC N/A
- VKTX N/A
- EPS
- UEC N/A
- VKTX N/A
- Revenue
- UEC $66,837,000.00
- VKTX N/A
- Revenue This Year
- UEC $36,993.31
- VKTX N/A
- Revenue Next Year
- UEC $7.07
- VKTX $338.60
- P/E Ratio
- UEC N/A
- VKTX N/A
- Revenue Growth
- UEC 70.62
- VKTX N/A
- 52 Week Low
- UEC $3.85
- VKTX $18.92
- 52 Week High
- UEC $10.88
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- UEC 64.53
- VKTX 36.68
- Support Level
- UEC $9.23
- VKTX $23.21
- Resistance Level
- UEC $10.78
- VKTX $26.74
- Average True Range (ATR)
- UEC 0.58
- VKTX 2.19
- MACD
- UEC -0.09
- VKTX -1.68
- Stochastic Oscillator
- UEC 80.33
- VKTX 14.67
About UEC Uranium Energy Corp.
Uranium Energy Corp is engaged in uranium mining and related activities. The company is working towards fueling the demand for carbon-free nuclear energy, a key solution to climate change, and energy source for the low-carbon future. The company is advancing its next generation of low-cost, environmentally friendly, in-situ recovery (ISR) mining uranium projects. The company has two extraction-ready ISR hub and spoke platforms in South Texas and Wyoming. UEC also has seven U.S. ISR uranium projects with all of their permits in place, with additional diversified holdings of uranium assets across the U.S., Canada and Paraguay.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.